Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations

Journal of Cardiovascular Electrophysiology

Volumn 22, Issue 6, 2011, Pages 698-705

  Sicouri, Serge ^a   Cordeiro, Jonathan M ^a   Talarico, Michael ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; antiarrhythmic drugs; atrial fibrillation; sodium channel blocker

Indexed keywords

ACETYLCHOLINE; CALCIUM CHANNEL; ENALAPRIL; ISOPRENALINE; LOSARTAN; POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; DEPOLARIZATION; DOG; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN; PULMONARY VEIN SLEEVE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART CONDUCTION SYSTEM; HEART RATE; LOSARTAN; PULMONARY VEINS;

EID: 79959209217     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2010.01972.x     Document Type: Article

References (29)

1. Fuster V,: Atrial fibrillation: An epidemiologic, scientific and clinical challenge. Nat Clin Pract Cardiovasc Med 2005; 2: 225. (Pubitemid 40846488)
2. Ehrlich JR, Hohnloser SH, Nattel S,: Role of angiotensin system and effects of its inhibition in atrial fibrillation: Clinical and experimental evidence. Eur Heart J 2006; 27: 512-518.
3. Nattel S, Burstein B, Dobrev D,: Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1: 62-73.
4. Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, Knackstedt C, Schimpf T, Mischke K, Gressner A, Hanrath P, Kelm M, Schauerte P,: Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1076-1082. (Pubitemid 47416566)
5. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, Chen SA,: Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 2006; 147: 12-22.
6. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I, Mann J, Matthew J, Pogue J, Yusuf S, Dagenais G, Lonn E,: Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154: 448-453. (Pubitemid 47271928)
7. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J,: Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841-1846. (Pubitemid 44297391)
8. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J,: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666. (Pubitemid 28402090)
9. Sicouri S, Glass A, Belardinelli L, Antzelevitch C,: Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008; 5: 1019-1026.
10. Sicouri S, Belardinelli L, Carlsson L, Antzelevitch C,: Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2009; 20: 803-810.
11. Burashnikov A, Antzelevitch C,: Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol 2006; 29: 290-295. (Pubitemid 43881405)
12. Patterson E, Po SS, Scherlag BJ, Lazzara R,: Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm 2005; 2: 624-631. (Pubitemid 40724130)
13. Patterson E, Lazzara R, Szabo B, Liu H, Tang D, Li YH, Scherlag BJ, Po SS,: Sodium-calcium exchange initiated by the Ca2+ transient: An arrhythmia trigger within pulmonary veins. J Am Coll Cardiol 2006; 47: 1196-1206.
14. Wongcharoen W, Chen YC, Chen YJ, Chen SY, Yeh HI, Lin CI, Chen SA,: Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents. Heart Rhythm 2007; 4: 1338-1349. (Pubitemid 47495729)
15. Lo LW, Chen YC, Chen YJ, Wongcharoen W, Lin CI, Chen SA,: Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins. Eur J Pharmacol 2007; 571: 197-208. (Pubitemid 47385897)
16. Sicouri S, Talarico M, Antzelevitch C,: Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeves. Heart Rhythm 2009; 6: S91.
17. + currents in cardiac Purkinje cells isolated from rabbit and dog. J Mol Cell Cardiol 2007; 42: 378-389. (Pubitemid 46135608)
18. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, Hocini M, Peng JT, Roudaut R, Clementy J,: Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101: 1409-1417. (Pubitemid 30169863)
19. Nattel S, Allessie MA, Haissaguerre M,: Spotlight on atrial fibrillation-the 'complete arrhythmia'. Cardiovasc Res 2002; 54: 197-203. (Pubitemid 34327900)
20. Nattel S,: Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: A new unifying concept with basic and clinical relevance. Heart Rhythm 2005; 2: 632-633. (Pubitemid 40724131)
21. Kawamura M, Imanishi M, Matsushima Y, Akabane S, Kuramochi M, Ito K, Omae T,: A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. Jpn J Pharmacol 1990; 54: 143-149. (Pubitemid 20329703)
22. Chen YJ, Chen SA, Chang MS, Lin CI,: Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: Implication for the genesis of atrial fibrillation. Cardiovasc Res 2000; 48: 265-273.
23. Chen YJ, Chen SA,: Electrophysiology of pulmonary veins. J Cardiovasc Electrophysiol 2006; 17: 220-224.
24. Sicouri S, Glass A, Carlsson L, Antzelevitch C,: Electophysiologic and antiarrythmic effects of AZD1305 in canine pulmonary vein sleeves. Heart Rhythm 2008; 5S: S163.
25. Burashnikov A, Antzelevitch C,: Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 2003; 107: 2355-2360. (Pubitemid 36578508)
26. Yu H, Gao J, Wang H, Wymore R, Steinberg S, McKinnon D, Rosen MR, Cohen IS,: Effects of the renin-angiotensin system on the current I(to) in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 2000; 86: 1062-1068. (Pubitemid 30367865)
27. Louch WE, Ferrier GR, Howlett SE,: Losartan improves recovery of contraction and inhibits transient inward current in a cellular model of cardiac ischemia and reperfusion. J Pharmacol Exp Ther 2000; 295: 697-704.
28. Sipido KR, Volders PG, Vos MA, Verdonck F,: Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: A new target for therapy? Cardiovasc Res 2002; 53: 782-805. (Pubitemid 34261018)
29. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di PG, Tognoni G,: Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617.